{"id":"W4220919246","doi":"10.1007/s00262-022-03159-8","title":"Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial","year":2022,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; London Health Sciences Centre; Centre Hospitalier Universitaire Sainte-Justine; University of Toronto; SickKids Foundation; Hospital for Sick Children","funders":"Merck KGaA; Pfizer","keywords":"Medicine; Refractory (planetary science); Cohort; Dosing; Avelumab; Adverse effect; Internal medicine; Open label; Surgery; Gastroenterology; Immunotherapy; Cancer; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001878062,0.0005903961,0.001151584,0.0001911499,0.0001982192,0.0006126883,0.000538648,0.0005765365,0.001865559],"category_scores_gemma":[0.001425687,0.0002055718,0.001029568,0.0003099922,0.0005542976,0.0005731614,0.000256658,0.002149519,0.0003986645],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007953581,"about_ca_system_score_gemma":0.0009261329,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003814281,"about_ca_topic_score_gemma":0.001544048,"domain_scores_codex":[0.9994386,0.0003263189,0.00004528107,0.00007069758,0.00006346192,0.00005562293],"domain_scores_gemma":[0.9987034,0.0003029269,0.0004812542,0.0001099645,0.00007876108,0.0003237431],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5270219,0.03230055,0.04060722,0.002974872,0.003863548,0.001067549,0.0008925985,0.004263097,0.0859393,0.0006968763,0.01040935,0.2899631],"study_design_scores_gemma":[0.4887969,0.4080514,0.06620796,0.0002177131,0.001471097,0.003104488,0.0001260053,0.002079745,0.01389402,0.0003663638,0.01562669,0.00005759417],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910546,0.005948927,0.0004050547,0.0003572491,0.00004544541,0.0005299642,0.0006428871,0.00003593567,0.0009799389],"genre_scores_gemma":[0.9882979,0.005245407,0.002099427,0.000667156,0.0001503864,0.0006546191,0.00219343,0.00002771925,0.0006641371],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001878062,"threshold_uncertainty_score":0.00993228,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04644449388634191,"score_gpt":0.3459004374383967,"score_spread":0.2994559435520547,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}